Journal of Pharmacopuncture (대한약침학회지)

KOREAN PHARMACOPUNCTURE INSTITUTE (대한약침학회)
권호 표지
DOI QR코드

DOI QR Code

Improvement Effect of Soyeom Pharmacopuncture on Gout via NLRP3 Inflammasome Regulation

  • Sung Wook, Kim (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Jun Ho, Lee (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Hyeonjin, Kim (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Seong Hoon, Lee (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Dajeong, Jeong (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Hyuk Soon, Kim (Department of Biomedical Sciences, College of Natural Science and Department of Health Sciences, The Graduate School of Dong-A University) ;
  • Cheol-Jung, Lee (Research Center for Materials Analysis, Korea Basic Science Institute) ;
  • Dae Yong, Kim (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Tae Han, Yook (Department of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Gabsik, Yang (Department of Korean Medicine, College of Korean Medicine, Woosuk University)
  • Received : 2022.10.20
  • Accepted : 2022.12.08
  • Published : 2022.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Gout is an inflammatory arthritis of the joints and soft tissues occurring due to deposition of monosodium urate (MSU) crystals, which are caused by persistent hyperuricemia. Soyeom pharmacopuncture is one treatment method that has been traditionally used for pain management in Oriental medicine. However, studies on its effect in reducing gout pain have been insufficient. Therefore, we selected Soyeom pharmacopuncture among natural products used in Korea as the new target of our study. Methods: The effects of Soyeom pharmacopuncture were examined in mouse models of acute gout induced by injection of MSU crystals into footpads. IL-1β, IL-6, and TNF-α production were examined by immunoblotting and enzyme-linked immunosorbent assay as hallmarks of NLRP3 inflammasome and cytokine activation. Results: Soyeom pharmacopuncture reduced foot edema in gout-induced mice, as well as IL-1β, nitrite, IL-6, and TNF-α production. Moreover, Soyeom pharmacopuncture also reduced MSU-induced gout inflammatory gene expressions, specifically those in the NF-kB pathway. Conclusion: Pharmacopuncture may serve as a new solution for other inflammatory diseases as well. Through active follow-up studies, we could thoroughly understand the clinical value of Soyeom pharmacopuncture.

Keywords

Acknowledgement

This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HF20C0145) and National Research Foundation of Korea (NRF) (NRF-2020R1I1A3072176) funded by the Korean government (Ministry of Science, ICT and Future Planning) and Woosuk University.

References

  1. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010;49(1):5-14. https://doi.org/10.1093/rheumatology/kep306
  2. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-55. https://doi.org/10.1016/S0140-6736(21)00569-9
  3. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38(5):628-32. https://doi.org/10.1002/art.1780380508
  4. Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516. https://doi.org/10.7326/0003-4819-143-7-200510040-00009
  5. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. https://doi.org/10.1002/art.22014
  6. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69.
  7. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-8. https://doi.org/10.1136/bmj.332.7553.1302
  8. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. Colchicine for acute gout. Cochrane Database Syst Rev. 2021;8(8):CD006190.
  9. Yook TH. Clinical observation about the extent of improvement of low back pain patient through medi-acupuncture therapy. J Korean Orient Med Soc. 1995;16(1):184-97.
  10. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639-47. https://doi.org/10.1038/nrrheum.2017.155
  11. Yang G, Yeon SH, Lee HE, Kang HC, Cho YY, Lee HS, et al. Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. Rheumatology (Oxford). 2018;57(4):727-36. https://doi.org/10.1093/rheumatology/kex499
  12. Yang G, Lee HE, Moon SJ, Ko KM, Koh JH, Seok JK, et al. Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis. Arthritis Rheumatol. 2020;72(7):1192-202.
  13. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271-83. https://doi.org/10.1038/nrrheum.2014.32
  14. Richette P, Bardin T. Should prednisolone be first-line therapy for acute gout? Lancet. 2008;372(9646):1301; author reply 1301-2.
  15. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19(6):329-36.
  16. Lee KH, Cho YY, Kim S, Sun SH. History of research on pharmacopuncture in Korea. J Pharmacopuncture. 2016;19(2):101-8. https://doi.org/10.3831/KPI.2016.19.010
  17. Bang M, Chang S, Kim JH, Min SY. Pharmacopuncture for asthma: a systematic review and a meta-analysis of randomized controlled trials. Eur J Integr Med. 2017;11:6-17. https://doi.org/10.1016/j.eujim.2017.03.006
  18. Wang JQ, Li XW, Liu M, Wang SC, Cao ZF. Inhibitory effect of Zanthoxylum bungeanum seed oil on ovalbumin-induced lung inflammation in a murine model of asthma. Mol Med Rep. 2016;13(5):4289-302. https://doi.org/10.3892/mmr.2016.5050
  19. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
  20. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. https://doi.org/10.1016/j.cell.2010.01.040
  21. Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116(8):2073-5. https://doi.org/10.1172/JCI29404
  22. Ozenver N, Efferth T. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases. Pharmacol Res. 2021;170:105710.
  23. Wortmann M, Klotz R, Kalkum E, Dihlmann S, Bockler D, Peters AS. Inflammasome targeted therapy as novel treatment option for aortic aneurysms and dissections: a systematic review of the preclinical evidence. Front Cardiovasc Med. 2022;8:805150.